Standard Biotools (LAB) Total Non-Current Liabilities (2010 - 2026)

Standard Biotools (LAB) has reported Total Non-Current Liabilities for 17 consecutive years, with $73.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 39.47% year-over-year to $73.5 million; the TTM figure through Mar 2026 stood at $73.5 million (down 39.47% YoY), while the FY2025 annual figure was $142.2 million, up 1.93% from the prior year.
• Total Non-Current Liabilities declined to $73.5 million in Q1 2026 per LAB's latest filing, from $142.2 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $248.3 million in Q1 2022 and bottomed at $73.5 million in Q1 2026.
• Historically, Total Non-Current Liabilities has averaged $159.0 million across 5 years, with a median of $158.7 million in 2023.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 37.29% — and 2026, when it tumbled 39.47%.
• Standard Biotools' Total Non-Current Liabilities stood at $159.6 million in 2022, then retreated by 0.48% to $158.8 million in 2023, then declined by 12.12% to $139.6 million in 2024, then rose by 1.93% to $142.2 million in 2025, then slumped by 48.3% to $73.5 million in 2026.
• Business Quant data shows LAB's Total Non-Current Liabilities at $73.5 million in Q1 2026, $142.2 million in Q4 2025, and $138.8 million in Q3 2025.